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Human NDE1 splicing and 
mammalian brain development
S. Mosca1,*, M. Raponi1,*, A. Meneghello2, E. Buratti3, C. G. Woods4 & D. Baralle1
Exploring genetic and molecular differences between humans and other close species may be the 
key to explain the uniqueness of our brain and the selective pressures under which it evolves. Recent 
discoveries unveiled the involvement of Nuclear distribution factor E-homolog 1 (NDE1) in human 
cerebral cortical neurogenesis and suggested a role in brain evolution; however the evolutionary 
changes involved have not been investigated. NDE1 has a different gene structure in human and 
mouse resulting in the production of diverse splicing isoforms. In particular, mouse uses the terminal 
exon 8 T, while Human uses terminal exon 9, which is absent in rodents. Through chimeric minigenes 
splicing assay we investigated the unique elements regulating NDE1 terminal exon choice. We found 
that selection of the terminal exon is regulated in a cell dependent manner and relies on gain/loss of 
splicing regulatory sequences across the exons. Our results show how evolutionary changes in cis as 
well as trans acting signals have played a fundamental role in determining NDE1 species specific splicing 
isoforms supporting the notion that alternative splicing plays a central role in human genome evolution, 
and possibly human cognitive predominance.
Alternative splicing is a complex mechanism used to regulate gene expression. This process allows different 
mature mRNAs to be produced from the same gene. The resulting diversity in amino acid sequence/content 
of the translated proteins isoforms may provide different biological functions1. Alternative splicing is regulated 
during the transcription and premRNA maturation, with splicing factors (regulatory proteins) interacting with 
cis-acting sequences in the pre-mRNA2,3. Changes in splicing regulatory sequences and proteins have strongly 
contributed to genome diversity by shaping alternative splicing signatures4–8. In this study we investigate splicing 
differences in the gene nudE nuclear distribution gene E homolog 1 (NDE1). NDE1 produces a protein vital to 
normal brain development. The gene is found on chromosome 16 and plays essential roles in microtubule organi-
zation, mitosis and within the central nervous system. Whilst this gene is crucial for cerebral cortex development 
it is also required for centrosome duplication, formation and function of the mitotic spindle9. The major NDE1 
transcript has nine exons and the corresponding protein has a predicted self-association domain, a LIS1 interac-
tion domain and a NUDE_C domain (c-terminal conserved region)10. In human pathology, NDE1 was identified 
via its interaction with Lissencephaly 1 (LIS1). The protein11 has a role in brain size and cortical lamination and 
possibly schizophrenia (via an interaction with the DISC1 protein)12,13. The splicing pattern of NDE1 is known to 
differ in human and mouse14, with mouse using terminal exon “8 T”, while human uses terminal exon 9, usually 
missing exon 8 T; generating different splicing products and different Nde1 proteins at the C-terminal domain. 
Interestingly, exon 8 T in human is included in the mature transcript thanks to the use of an alternative 5′ ss and is 
joined to exon 9. This minor human transcript uses exon 8 T as a terminal coding exon due to the presence of an 
in frame stop codon. As a result, there appears to have been a change through mammal evolution that must have 
led to a decreasing 8 T use and increasing 9 use (that is humans almost obligatory) (Fig. 1A,B). An interesting 
observation is that deletion of NDE1 produces mice with small brains but humans with homozygous loss of this 
gene have a severe phenotype with severe microcephaly and mental retardation)14. Part of this significant clinical 
difference may be explained by the differences in the splicing process between the two models.
In this study, we characterize the splicing pattern in mouse and human models of NDE1, to understand how 
this different terminal exon usage has evolved in these two organisms. Using primary brain samples and minigene 
approaches, our results show that evolutionary changes in cis as well as trans acting elements are essential deter-
minants of NDE1 terminal exon choice.
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Results
Characterization of NDE1 splicing pattern: differences between human and mouse. Endogenous 
NDE1 expression was tested in several human and mouse tissues to assess eventual differences in NDE1 splicing 
products. Human NDE1 expression was analysed by examining fetal human tissues (kindly prepared by Professor 
D. Wilson, Southampton), and in HeLa, SK-N-SK and Hek-293 cell lines. With endogenous NDE1 primers 
(Materials and Methods, 2.4) we obtained three bands for each sample (Fig. 2A). Two of the three products 
observed were as expected: a higher band corresponding to the full- length splicing product of NDE1 including 
exon 7, exon 8, exon 8 T and exon 9 (Fig. 2A, lanes 1 to 6 and 8). A more intense band, corresponding to exon 8 T 
skipping was present in all samples (Fig. 2A, lanes 1 to 8). Interestingly a third lower band was also observed in all 
samples (Fig. 2A, lanes 1 to 8), representing a new splice isoform, not previously reported, that is formed following 
exclusion of both exon 8 and exon 8 T in humans. We called this isoform “Delta8” (∆ 8). The identity of all these 
bands was confirmed by direct sequencing, quantification is reported below each lane. In parallel, we analysed 
endogenous mouse NDE1 expression in several mouse tissues (kindly prepared by Dr Eve and Dieter Riethmacher) 
and cell lines, Neuro2a, and Mouse fibroblast cell lines. Using mouse endogenous NDE1 primers (Materials 
and Methods, 2.4) we obtained two bands: the higher band originated from use of an alternative 3′ splice 
site in exon 8 T (Fig. 2B, lanes 1 to 8); and a more intense band corresponding to the main splicing isoform that 
includes the joining together of exons 7, 8, and 8 T (Fig. 2B, lanes 1 to 8). In mouse, exon 9 is never used. The 
identity of these mouse RT-PCR bands were confirmed by sequencing (data not shown). Mouse uses a 3′ UTR 
following 8 T while in human the inclusion of exon 8 T is triggered by a 5′ ss 32 bp downstream the stop codon.
To extend our knowledge of the relationship between the two models, we transfected SK-NSH, Hek-293, HeLa, 
Mouse Fibroblast and Neuro2a cell lines with human and mouse minigenes that carried these sequences (see 
Materials and Methods, 2.1; 2.3) (Fig. 3A, lanes 1-5). The splicing pattern observed in the minigenes was similar to 
endogenous expression although some differences in band intensities were observed, as confirmed by quantifica-
tion. In particular, cells with human minigenes show three bands with different intensities that, when sequenced, 
were confirmed to represent the following splicing events: full transcript (7-8-8T-9), skipping of exon 8 T (7-8-9) 
and skipping of exon 8, ∆ 8 isoform (7–9) (Fig. 3A, lanes 1–5). Similarly, the two bands observed from the mouse 
minigene were shown to correspond with isoform including exons 7, 8, and 8 T but not exon 9. As observed 
in the endogenous gene, the difference in size in the two products is due to the use of an alternative 3′ splice 
site in exon 8 T (Fig. 3B, lanes 1–5). Interestingly the percentage of exon 8 T exclusion for the human minigene 
was much higher in mouse (Mouse Fibroblast and Neuro2a, 79% and 65% respectively, Fig. 3A lanes 4–5) com-
pared to human cell lines (SH-N-SH, Hek-293 and HeLa, 40%, 37%, and 39% respectively, Fig. 3A lanes 1–3).
To understand the evolution in usage of the terminal exon 8 T and 9 we compared the sequence of these exons 
between human, mouse and Gallus and analysed the mechanism of modulation of the splicing process. The 
nucleotide differences between these regions are highlighted in (Fig. 4). Differentiated fibroblast cell lines derived 
from Gallus (dt40 cell line) kindly prepared by Marco Baralle, (ICGEB, Trieste) show the same NDE1 splicing 
pattern as mouse fibroblast (data not shown). As shown in Fig. 4, this comparison allowed identification of several 
Figure 1. Alternative splicing scheme in human (green/gray) and mouse (orange/red) models and 
schematic representation of minigene constructs used in this study. Grey arrows represent pCDNA3 vector 
where the partial NDE1 genomic sequence was cloned under the control of the CMV promoter. (A) Terminal 
human NDE1 structure. The main UTR region is after exon 9. It is interesting to note that after exon 8 T there 
is a 5′ splice site, this produces the minor isoform including exon 8 T with its own stop codon, part of intron 8 
and exon 9. Continuous lines represent major splicing events, dotted lines represent alternative splicing events 
with exon 8 T inclusion. (B) Terminal mouse NDE1 structure. The gene uses exon 8 T as its terminal exon; the 
splicing product excludes exon 9; continuous lines represent the constitutive splicing event. (C) The human 
minigene construct consisting of human exon 7, exon 8, exon 8 T and exon 9, including partial intron flanking 
sequence. The 3′ UTR belongs to pCDNA3+ . (D) The mouse minigene construct consisting of human exon 7, 
exon 8, mouse exon 8 T and mouse exon 9; including partial intron flanking sequences. The 3′ UTR belongs to 
pCDNA3+ . (E)The chimeric minigene called 8Th9m is a human minigene with the human exon 9 replaced by 
the mouse exon 9. The 3′ UTR belongs to pCDNA3+ .
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nucleotide sequence differences that could be potentially responsible for the different splicing patterns observed 
in the various human and mouse tissues/cell lines.
Terminal exon choice is modulated by cis-acting sequences. In order to address the potential signif-
icance of these nucleotide differences, several nucleotides were substituted in the human NUDE1 minigene with 
the corresponding mouse sequence by site-directed mutagenesis (favouring common sequences between gallus 
and mouse) (Fig. 4). In this way one minigene for each mutation was generated which was transiently transfected 
into SK-N-SH cell lines for splicing analyses (Fig. 5A). Nucleotide substitutions on human exon 9 in minigenes 
M9c (G > C), M9g (A > G), M9gc (A > G and A > C) produced a weak effect on exon 9 splicing by favouring 
the production of the 8 TplusEx9 isoform (Fig. 5B, lanes 4–6). The strongest effect was observed with M9g with 
increased inclusion of exon 8 T (Fig. 5B, lane 5, 60% inclusion). We also analysed the effect of the chimeric mini-
gene 8th9m in which the entire exon 9 was replaced with mouse exon 9. In this case, we see a stronger effect on 
exon 8 T inclusion (85%) favouring the production of the full isoform including all exons (Fig. 5B lane 2). The 
effects of nucleotide substitutions on exon 8 T in human minigenes that carried the following substitution was 
also analysed: M1 (G > A and G > A; Figs 4B and 5A) and M3 (C > G, C > G, T > C, G > A, T > G, T > A, T > C, 
G > A, C > G; Figs 4B and 5A). As shown in Fig. 5C, lanes 2–4, the minigenes carrying substitutions M1 and M3 
decrease the inclusion of exon 8 T to 37% and 26% respectively, with the exception of M2 (G > A and A > G) that 
increases inclusion to 57%. The splice factors tested were chosen by looking at the nucleotide substitutions in exon 
8 T, and observing which consensus sequences were affected (Fig. 4B), as predicted using SpliceAid15.
Changes in splicing factor expression mediate NDE1 alternative splicing. In order to investigate 
the role of splicing factors in the human NDE1 splicing, we focused on polypyrimidine tract-binding proteins 
(PTB), neural PTB (nPTB) and heterogeneous nuclear ribonucleoprotein H (hnRNP H), as these factors have 
consensus sequences in human exon 8 T (Fig. 4B) that are disrupted in the generated mutant M1 (hnRNP H) and 
Figure 2. Analysis of endogenous NDE1 splicing. All gels were run under the same experimental 
conditions and the experiments were repeated at least 3 times. (A) Endogenous NDE1 splicing pattern in 
human tissues (from the same foetus) and human cell line (HeLa, SK-N-SK, Hek-293)s; The oligonucleotides 
used to amplify the endogenous gene were positioned in exon 7 (forward oligo) and 9 (reverse oligo).  
(B) Endogenous NDE1 splicing pattern in mouse tissues (from the same mouse) and mouse cell lines (Neuro2a 
and mouse fibroblast). The percentage of exon 8 T inclusion is 100% in all samples. The higher band indicated 
with (b) is originated from the use of an alternative 3′ splice site upstream the canonical 3′ ss of exon 8 T. The 
oligonucleotides used to amplify the endogenous genes were positioned in exon 7 (forward oligo), 8 T (reverse 
oligo) and pseudo exon 9 (reverse oligo) in mouse.
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M3 (PTB). We performed knockdown experiments of these factors in SK-N-SH cell lines transfected with the 
human or mutated M1, M3 minigenes.
Western blot was performed to confirm knock down (Supplementary Figure 1A). Using ImageJ software 
(http://imagej.nih.gov/ij/), the amplified cDNA bands from the splicing assay were measured for calculation of 
percentage skipping of exon 8 T in each sample. We observed no statistically significant difference in the splicing 
pattern of NDE1 between hnRNP H knockdown and control siRNA (Supplementary Figure 1B).
We the analysed the contribution of PTB and its neuronal form nPTB to NDE1 terminal exon splicing. The 
human NDE1 minigene was transfected in the following circumstances: 1) with both PTB and nPTB knockdown 
(Fig. 6A, lane 2); 2) PTB knockdown plus overexpression of nPTB (Fig. 6A, lane 3) 3) nPTB overexpression 
(Fig. 6A, lane 4) and compared to 4) siRNA control with the human NDE1 minigene transfection (Fig. 6A, lane 1).
Unlike hnRNP H, these experiments showed important changes between control conditions and the siRNA 
assay for PTB and nPTB (Fig.6 A,B). When PTB and nPTB were knocked down, we observed increased skipping 
of exon 8 T (Fig. 6A, lane 2, from 43% to 24%). In conditions where nPTB is overexpressed we see similar results 
to the control, showing that nPTB is enough to rescue the knockdown effect (Fig. 6A, lanes 3 and 4). To analyse 
whether this PTB/nPTB effect was dependent on the regulatory sequence predicted in exon 8 T, we repeated the 
same experiment analysing the differences between control conditions and PTB siRNA following transfection 
of the mutant minigene M3 (which does not contain the consensus sequence in exon 8 T for PTB or nPTB). The 
results reported in Fig. 6B, lane 2 show very little no changes in the splicing pattern of the mutant M3 minigene 
following knockdown of PTB/nPTB confirming that the mutated region in the M3 minigene is a binding site for 
PTB.
Figure 3. All gels were run under the same experimental conditions and the experiments were repeated 
at least 3 times. Dotted lines indicate cropping within the same gels. (A) NDE1 splicing pattern in cell lines 
transfected with human NDE1 minigene. (B) NDE1 splicing pattern in cell lines transfected with mouse NDE1 
minigene. The higher band indicated with (b) is originated from the use of an alternative 3′ splice site upstream 
the canonical 3′ ss of exon 8 T. The faint lower band was not characterised due to the inability to sequence it.
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Discussion
Nde1 has recently been shown to be critical for cerebral cortex development and mutations in the gene are 
involved in severe disorders of microcephaly (reduction of brain size, but particularly of cerebral cortex size) and 
lissencephaly10,13,14. Interestingly a more severe phenotype was seen in human microcephaly compared with mice 
Figure 4. Exon 9 and 8 alignment. Alignment was performed using Ensemble (http://www.ensembl.org/
index.html). In red are highlighted the common mismatches between human and mouse sequence; in green 
are highlighted the mismatches between all three organisms. The star (*) indicates conserved nucleotides. The 
sequence changes created separately in the human minigene for transforming it to a more mouse-like genotype 
are highlighted in blue. (A) Alignment of exon 9. The 3′ ss, upstream human exon 9, is shown in bold. The 
human stop codon is underlined. (B) Alignment of exon 8 T. Part of the 3′ ss upstream exon 8 T is shown in bold 
characters. Splicing regulatory proteins predicted with SpliceAid to bind exon 8 T are indicated.
Figure 5. NDE1 Splicing pattern in SK-N-SH cells transfected with minigenes for each mismatch analysed. 
All gels were run under the same experimental conditions and the experiments were repeated at least 3 times. 
(A) Scheme of minigenes with nucleotide substitutions in exon 8 T and 9. (B) Analysis of exon 9 mutants and of 
human minigene with mouse exon 9. (C) Analysis of exon 8 T mutants.
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with the same gene fault14. We postulate that this can be in part explained by differences in alternative splicing 
processes between the two models; given that mouse and human NDE1 produce different terminal exons.
Several studies have described how alternative gene splicing across genomes can lead to loss or gain of particu-
lar traits by subtle alteration of genes function16–21. Of relevance, Lin et al. reported the existence of human spe-
cific splicing patterns in the brain; that such patterns affect protein domains, and are greatly influenced by changes 
in cisregulatory sequences5. Another study indicated that changes in conserved cis- regulatory elements of splic-
ing are responsible of the majority of differences in alternative splicing in human and mouse and suggest that 
also changes in splicing factors acting in trans contributes to the evolutionary landscape of alternative splicing22.
In this work, we analysed the difference in NDE1 splicing patterns in human and mouse, focusing on terminal 
exon choice and the regulatory elements involved. Analysing cell lines and mouse tissues, we observed that exon 
8 T is always the last exon and exon 9 is never included in mouse. Conversely, analysing human fetal tissue and 
cell lines we show that human NDE1 produces a main splicing isoform excluding exon 8 T, with exon 9 as the 
terminal coding exon plus a minor isoform including both exon 8 T and 9 (exon 8 T would be the terminal cod-
ing exon). This is in accordance with previously reported work in adult human tissues23 (note that in Bradshaw 
et al. exon8T = 8b, exon9 = 8a). Interestingly, we also saw an additional splicing event corresponding to skipping 
of exon 8 and 8 T together not previously reported. Exon 8 is 152 nucleotides long. Its exclusion from the final 
human NDE1 trancript causes frameshift and a new stop codon used in exon 9. The putative protein differs by 80 
aminocids at the c-terminal compared to the main isoform. This appears in all our experiments (both endogenous 
and human minigene analysis) and better defines the complexity of the alternative splicing process of NDE1.
Therefore at least 3 different c-termini are produced in human NDE1 proteins, while only one is 
produced in mouse, corresponding to the minor human isoform including exon 8 T. The 3 possible c-termini 
in human NDE1 are: GLDTSCRWLSKSTTRSSSSC (main isoform); VGHELPLVVQINNQVVQLLLKPVLGLFQFI 
ISGRLLLVLLGEVLDLLLEPLLPLFQSFH GAGKVLQLLLRVGELQGQRPG (isoform skipping exon 8); GLGKRLE 
FGKPPSHMSSSPLPSAQGVVKMLL (isoform including exon 8 T).
This is highly important from an evolutionary point of view since crucial amino acids for NDE1 function 
(interaction with other protein at the centromere) have been described in the c-terminus of the main human iso-
form (for review see24). These include a palmitoylation site (amino acid C274), and 7 phosphorylation sites (Y279, 
S282, S291, S306, S307, T308, S309) corresponding to exon 8.
Although particular active amino acid sites have not been reported for NDE1 in correspondence to exon 9, an 
important role of this exon in NDE1 function should not be excluded. For instance, NDE1 exon 9 may contain 
important regulatory sequences for RNA transport and/or stability that in turn might regulate the expression of 
NDE1 at protein level.
The c-terminal domain of NDE1 produces different intra and inter species NDE1 isoforms and we have estab-
lished the elements regulating selection of the terminal coding exon in humans. We identified these elements 
using chimeric minigenes for splicing assay and comparing alternative splicing regulation between mouse and 
human cell lines. Intriguingly, transfection of the human minigene resulted in a different splicing pattern when 
transfected in mouse cell lines compared to human cell lines, suggesting that expression level of transacting 
Figure 6. Analysis of the effect of PTB and nPTB on NUDE1 and M3 minigenes splicing. Gels were run 
under the same experimental conditions and the experiments were repeated at least 3 times. Dotted lines 
indicate cropping within the same gels. (A) NDE1 splicing pattern in SK-N-SH cells transfected with human 
NDE1 minigene and (1) luciferase siRNA control; (2) siRNA for PTB and nPTB; (3) siRNA for PTB and nPTB, 
but with overexpression of nPTB (siRNA resistant27); (4) human NDE1 control with nPTB overexpression.  
(B) Chart showing band intensity percentage of 8 T skipping, relative to panel A; (C) NDE1 splicing pattern 
in SK-N-SH cells transfected with M3 minigene. (1) Control luciferase siRNA and transfection of tM3 
minigene;(2) siRNA for PTB and nPTB with human NDE1 minigene transfection. (D) Chart of band intensity 
percentage and skipping of exon 8 T, relative to panel C.
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factors also plays an important role in this process. For example, exon 8 T was almost completely skipped from 
the human minigene pre-mRNA in mouse cell lines. This suggests the presence of different regulatory trans act-
ing factors of splicing between human and mouse; or a different functionality of those factors between the two 
species.
With this pattern the role of cis and trans elements in the regulation of the NDE1 alternative splicing process 
are likely to be important. To investigate the role of cis elements we substituted human nucleotides in exon 8 T 
and exon 9 with mouse mismatches and we investigated changes in the splicing process. Replacement of human 
exon 9 with the mouse exonic sequence in the minigene human exon 8 T/mouse exon 9 resulted in inclusion of 
human exon 8 T (Fig. 6A). However, single nucleotide substitutions were only in part able to recapitulate this 
effect, suggesting the presence of regulatory cis acting elements of splicing regulation all along exon 9, which act 
cooperatively.
We also identified an important silencer regulatory region in human exon 8 T, which when mutated (M2, 
Figs 4 and 5) results in increased inclusion of exon 8 T. Conversely, another two regions in human exon 8 T seem 
to act as enhancers of this exons’ splicing; and these regions mutated (M1 and M3) result in increased skipping 
of exon 8 T.
We subsequently focussed on PTB and nPTB since these important regulatory proteins of splicing are involved 
in brain development25 and were predicted by SpliceAid to bind human NDE1 exon 8 T (the enhancer region 
mutated in the M3 minigene) but not mouse.
Knock down of these splicing regulatory proteins had a strong effect on exon 8 T splicing of the human mini-
gene demonstrating their role in the regulation of NDE1 processing. On the other hand, knockdown of PTB/
nPTB had no effect on the minigene with the mutated region M3, confirming a central role of this sequence in 
the regulation of exon 8 T inclusion through binding of PTB. These results also confirm the role of PTB as an 
enhancer of NDE1 exon 8 T splicing. This is an unusual mechanism of splicing regulation by PTB which normally 
acts as a silencer of splicing, here essentially acting as an enhancer of exon inclusion through binding of elements 
in the downstream intron rather than within the exon26. Moreover, this, represents a mechanism of splicing reg-
ulation through an enhancer sequence which is unusually distant from the splice sites (48 nucleotides from the 
3′ ss and 78 nucleotides from the 5′ ss). Overall this finding underlines the importance of performing comparative 
genomic analysis to uncover unusual splicing regulatory mechanism which would be otherwise underestimated.
In conclusion, we provide an overview of the NDE1 splicing process in human and mouse models: model 
mammals with particularly large and small cerebral cortices respectively. We describe a new isoform excluding 
exons 8 and 8 T, that PTB/nPTB are important splice factors functioning as distant enhancers, and that this has 
changed during species evolution as has cerebral cortex size. Future work would include testing other splicing 
regulatory elements responsible for exon 8 exclusion and to investigate the function of different NDE1 c-terminal 
domains.
Methods
Minigene construction. The minigenes containing different combinations of mouse or human exons are 
shown in Fig. 1C,D,E. They consist of four exons (including part of their flanking introns). These were cloned in 
a modified version of the pCDNA3(+ ) vector (Invitrogen) under CMV promoter control. 4 inserts were ampli-
fied and cloned separately with specific primers and restriction enzymes. Restriction enzymes used for cloning 
were HindIII/KpnI for exon 7 (insert 1); KpnI/BAMHI for exon 8 (insert 2); BAMHI/Xho for exon 8 T (insert 3) 
and Xho/Xba for exon 9 (insert 4). Digested PCR products were purified by gel electrophoresis and ligated into 
a linearized pCDNA3 vector. Ligation reactions were incubated overnight at room temperature and added to 
competent Escherichia coli strain DH5a for transformation. Bacterial colonies were grown in LB broth containing 
ampicillin at a final concentration of 50 mg/ml. Plasmid DNA was extracted using Miniprep kit of Qiagen and 
sent for sequencing.
Cell Culture. Several mammalian cell lines were used for transfection experiments including SK-N-SK 
(human neuroblastoma cell line), Hek-293 (Human Embryonic Kidney 293 cells), HeLa (human cervical cancer 
immortal cell line), Neuro2A (murine neuroblastoma cell line) and Mouse fibroblast cell line. Mouse project 
licence, PPL30/2692. Fetal tissues were obtained with informed consent and according to the protocol ethically 
approved by Southampton and South West Hants LREC. Cells were grown and maintained in Petri dishes or 
75 mm2 flasks at 37 °C with 5% CO2 in Gibco® DMEM Dulbecco’s Modified Eagle Medium (Life Technologies) 
enriched with 10% Gibco® FBS (Fetal Bovine Serum; Life Technologies). Antibiotics (100 μg/ml Penicillin, 
Streptomycin; Sigma Aldrich) were added when required. Once the cultures reached the appropriate plating den-
sity, they were split and medium was replaced. The desired concentration of cells to be plated was determined by 
counting the cultured cells with the Neubauer Chamber2 and dispensing the correct volume of suspension into 
the well. Cell cultures were preserved by freezing and storing them at − 80 °C. Cells were trypsinized, pelleted and 
resuspended in 1.5 ml of freezing medium (90% FBS and 10% DMSO).
siRNA, transfection and PCR assays. Mouse minigene and Human minigene were transfected into 
Mouse fibroblasts and Neuro2a following standard protocols with a 3:1 FuGENE® 6 Transfection Reagent:DNA 
ratio (Promega). For silencing, 20 nM siRNAs for PTB and nPTB27 and 20 nM siRNA for hnRNP H (Sigma) were 
transfected separately into 28 × 103 SK-N-SH cell line with the INTERFERin® reagent (Polyplus transfection). 
Cells were grown overnight and fresh complete medium was added to repeat the siRNA assay. Cells were grown 
for additional 48 h for siPTB and sinPTB assays and 24 h for sihnRNP H assay. Total RNA was extracted using an 
RNeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. Total RNA (1 μ g) was 
reversetranscribed using random hexamer primers (Promega) and cDNA was then amplified by PCR using the 
FastStart Taq DNA Polymerase (ROCHE) in a total volume of 50 μ L with primers specifically designed to amplify 
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processed transcripts derived from the minigene (95 °C for 4 minutes, followed by 95 °C for 30 seconds, 54 °C for 
30 seconds, 72 °C for 45 seconds, and final extension at 72 °C for 7 minutes). Each transfection experiment was 
performed at least in triplicate.
Primers. Human:
nudHex7 F: 5′ -ATATCAGCCCTCAACATTGT,
9endR: 5′ -AGACCAAGAACAGGCTTCA
NewT7 F: 5′ -GACTCACTATAGGGAGACCCA,
Hex9Rev: 5′ -TTGGACAACCAGCGGCAACT
Mouse:
NewT7 F: 5′ -GACTCACTATAGGGAGACCCA,
NewM8T R: 5′ -TGGCTCTTATTTCTCAAACTAC,
Hex9Rev: 5′ -TTGGACAACCAGCGGCAACT.
Western blot. siRNA assays samples were electroblotted onto a Hybond-C Extra membrane (Amersham, 
Chalfont St Giles, UK), and antibody recognition was performed using in-house or commercial antibodies. A 
blocking solution was added to cover the membrane: the buffer contained 3–5% lyophilised milk for alimentary 
use, 1X PBS and 0.1% Tween20. The membrane was incubated for at least one hour and washed again with 1X 
PBS. The membrane was consequently incubated with the specific primary antibody, diluted in 1X PBS + 0.1% 
Tween20 and 3% BSA, for 1–2 hours. The membrane was washed with 1X PBS three times, and incubated with 
the appropriate secondary antibodies for 1–2 hours and washed again. Protein bands were detected using an 
enhanced chemiluminescence kit (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. The 
following antibodies were used in this study: Polyclonal Anti-PTB antibody produced in rabbit (in house from 
ICGEB, Trieste, Italy); dilution: 1:1000. Polyclonal Anti-hnRNP H antibody produced in rabbit (SIGMA; catalogue 
number: SAB4501422); dilution: 1:500 Anti-Calnexin antibody (Abcam; catalogue number: ab22595); dilution: 
1:1000. Anti-Rabbit secondary antibody (Dako); dilution: 1:2000.
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